Indaptus Therapeutics/$INDP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Indaptus Therapeutics
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
Ticker
$INDP
Sector
Primary listing
Employees
5
Headquarters
Website
INDP Metrics
BasicAdvanced
$6.3m
-
-$21.58
1.00
-
Price and volume
Market cap
$6.3m
Beta
1
52-week high
$13.40
52-week low
$1.51
Average daily volume
57k
Financial strength
Current ratio
1.512
Quick ratio
1.381
Profitability
EBITDA (TTM)
-19.833
Management effectiveness
Return on assets (TTM)
-148.91%
Return on equity (TTM)
-587.59%
Valuation
Price to book
1.93
Price to tangible book (TTM)
1.93
Price to free cash flow (TTM)
-0.182
Free cash flow yield (TTM)
-547.98%
Free cash flow per share (TTM)
-15.343
Growth
Earnings per share change (TTM)
-52.00%
3-year earnings per share growth (CAGR)
-23.68%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Indaptus Therapeutics stock?
Indaptus Therapeutics (INDP) has a market cap of $6.3M as of May 01, 2026.
What is the P/E ratio for Indaptus Therapeutics stock?
The price to earnings (P/E) ratio for Indaptus Therapeutics (INDP) stock is 0 as of May 01, 2026.
Does Indaptus Therapeutics stock pay dividends?
No, Indaptus Therapeutics (INDP) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next Indaptus Therapeutics dividend payment date?
Indaptus Therapeutics (INDP) stock does not pay dividends to its shareholders.
What is the beta indicator for Indaptus Therapeutics?
Indaptus Therapeutics (INDP) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.